Carboplatin, Gemcitabine, and Mifepristone for Advanced Breast Cancer and Recurrent or Persistent Epithelial Ovarian Cancer

Trial Profile

Carboplatin, Gemcitabine, and Mifepristone for Advanced Breast Cancer and Recurrent or Persistent Epithelial Ovarian Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Mifepristone (Primary) ; Carboplatin; Gemcitabine
  • Indications Advanced breast cancer; Fallopian tube cancer; Male breast cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Dec 2017 Planned End Date changed from 1 Nov 2017 to 1 Jun 2018.
    • 05 Dec 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Jun 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top